[开放获取]   阿普米司特治疗银屑病专家指导意见（2025版）

doi:10.35541/cjd.20240155

Abstract

Abstract: 【Abstract】 Apremilast is the first oral targeted small-molecule drug approved for the treatment of psoriasis in China. Due to mechanisms underlying the specific regulatory effect of apremilast on the balance of inflammation via targeting phosphodiesterase 4, it has been widely used for the treatment of various types of psoriasis. Many studies have confirmed that apremilast is effective in the treatment of mild to severe plaque psoriasis, psoriasis in special areas, psoriatic arthritis, palmoplantar pustulosis, and pediatric psoriasis, with good safety and tolerability profiles. Based on the pharmacological mechanisms of apremilast and clinical data on the treatment of psoriasis, the Committee on Psoriasis, Chinese Society of Dermatology convened relevant experts to develop this proposal to ensure the standardized, reasonable, safe and effective use of apremilast in the treatment of psoriasis.

Key words: Psoriasis, Apremilast, Phosphodiesterase 4 inhibitors, Oral administration, Expert proposal

Committee on Psoriasis, Chinese Society of Dermatology. Expert proposal on apremilast for the treatment of psoriasis （2025 edition）[J]. Chinese Journal of Dermatology, 2025, 58(5): 416-424.doi:10.35541/cjd.20240155

References ［90］

［1］	Griffiths C, Armstrong AW, Gudjonsson JE, et al. Psoriasis［J］. Lancet, 2021,397（10281）:1301⁃1315. doi: 10.1016/S0140⁃6736（20）32549⁃6.
［2］	李慧贤, 胡丽, 郑焱, 等. 基于全球疾病负担（GBD）大数据的中国银屑病流行病学负担分析［J］. 中国皮肤性病学杂志, 2021,35（4）:386⁃392. doi: 10.13735/j.cjdv.1001⁃7089.202003197.
［3］	Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis［J］. Biochem Pharmacol, 2012,83（12）:1583⁃1590. doi: 10.1016/j.bcp.2012.01.001.
［4］	Li H, Zuo J, Tang W. Phosphodiesterase⁃4 inhibitors for the treatment of inflammatory diseases［J］. Front Pharmacol, 2018,9:1048. doi: 10.3389/fphar.2018.01048.
［5］	Schett G, Sloan VS, Stevens RM, et al. Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases［J］. Ther Adv Musculoskelet Dis, 2010,2（5）:271⁃278. doi: 10.1177/1759720X10381432.
［6］	Deeks ED. Apremilast: a review in psoriasis and psoriatic arthritis［J］. Drugs, 2015,75（12）:1393⁃1403. doi: 10.1007/s40265⁃ 015⁃0439⁃1.
［7］	Huh KY, Choi Y, Nissel J, et al. Pharmacokinetics and tolerability of apremilast in healthy Korean adult men［J］. Clin Transl Sci, 2021,14（4）:1505⁃1511. doi: 10.1111/cts.13013.
［8］	Okubo Y, Ohtsuki M, Komine M, et al. Population pharmacokinetic and exposure⁃response analysis of apremilast in Japanese subjects with moderate to severe psoriasis［J］. J Dermatol, 2021,48（11）:1652⁃1664. doi: 10.1111/1346⁃8138. 16068.
［9］	Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate⁃to⁃severe plaque psoriasis over 52 weeks: a phase Ⅲ, randomized controlled trial （ESTEEM 2）［J］. Br J Dermatol, 2015,173（6）:1387⁃1399. doi: 10.1111/bjd.14164.
［10］	Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 （PDE4） inhibitor, in patients with moderate to severe plaque psoriasis: results of a phaseⅢ, randomized, controlled trial （Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis ［ESTEEM］ 1）［J］. J Am Acad Dermatol, 2015,73（1）:37⁃49. doi: 10.1016/j.jaad.2015.03. 049.
［11］	Stein Gold L, Papp K, Pariser D, et al. Efficacy and safety of apremilast in patients with mild⁃to⁃moderate plaque psoriasis: results of a phase 3, multicenter, randomized, double⁃blind, placebo⁃controlled trial［J］. J Am Acad Dermatol, 2022,86（1）:77⁃85. doi: 10.1016/j.jaad.2021.07.040.
［12］	Stein Gold L, Bagel J, Lebwohl M, et al. Efficacy and safety of apremilast in systemic⁃ and biologic⁃naive patients with moderate plaque psoriasis: 52⁃week results of UNVEIL［J］. J Drugs Dermatol, 2018,17（2）:221⁃228.
［13］	Ioannides D, Antonakopoulos N, Chasapi V, et al. A real⁃world, non⁃interventional, prospective study of the effectiveness and safety of apremilast in bio⁃naïve adults with moderate plaque psoriasis treated in the routine care in Greece ⁃ the 'APRAISAL' study［J］. J Eur Acad Dermatol Venereol, 2022,36（11）:2055⁃2063. doi: 10.1111/jdv.18166.
［14］	Rich P, Gooderham M, Bachelez H, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult⁃to⁃treat nail and scalp psoriasis: results of 2 phaseⅢ randomized, controlled trials （ESTEEM 1 and ESTEEM 2）［J］. J Am Acad Dermatol, 2016,74（1）:134⁃142. doi: 10.1016/j.jaad.2015.09.001.
［15］	Spencer RK, Elhage KG, Jin JQ, et al. Apremilast in palmoplantar psoriasis and palmoplantar pustulosis: a systematic review and meta⁃analysis［J］. Dermatol Ther （Heidelb）, 2023,13（2）:437⁃451. doi: 10.1007/s13555⁃022⁃00877⁃w.
［16］	Bissonnette R, Pariser DM, Wasel NR, et al. Apremilast, an oral phosphodiesterase⁃4 inhibitor, in the treatment of palmoplantar psoriasis: results of a pooled analysis from phaseⅡ PSOR⁃005 and phaseⅢ Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis （ESTEEM） clinical trials in patients with moderate to severe psoriasis［J］. J Am Acad Dermatol, 2016,75（1）:99⁃105. doi: 10.1016/j.jaad.2016.02.1164.
［17］	Merola JF, Parish LC, Guenther L, et al. Efficacy and safety of apremilast in patients with moderate⁃to⁃severe genital psoriasis: results from DISCREET, a phase 3 randomized, double⁃blind, placebo⁃controlled trial［J］. J Am Acad Dermatol, 2024,90（3）:485⁃493. doi: 10.1016/j.jaad.2023.10.020.
［18］	Jonak C, Göttfried I, Perl⁃Convalexius S, et al. Characteristics and outcomes of patients with psoriasis treated with apremilast in the real⁃world in Austria ⁃ results the APPRECIATE study［J］. Ther Adv Chronic Dis, 2023,14:20406223231152785. doi: 10.1177/20406223231152785.
［19］	Mrowietz U, Barker J, Conrad C, et al. Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: results from the EMBRACE randomized trial［J］. J Eur Acad Dermatol Venereol, 2023,37（2）:348⁃355. doi: 10.1111/jdv.18689.
［20］	Kavanaugh A, Gladman DD, Edwards CJ, et al. Long⁃term experience with apremilast in patients with psoriatic arthritis: 5⁃year results from a PALACE 1⁃3 pooled analysis［J］. Arthritis Res Ther, 2019,21（1）:118. doi: 10.1186/s13075⁃019⁃1901⁃3.
［21］	Kavanaugh A, Mease PJ, Gomez⁃Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo⁃controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor［J］. Ann Rheum Dis, 2014,73（6）:1020⁃1026. doi: 10.1136/annrheumdis⁃2013⁃205056.
［22］	Cutolo M, Myerson GE, Fleischmann RM, et al. A phaseⅢ, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial［J］. J Rheumatol, 2016,43（9）:1724⁃1734. doi: 10.3899/jrheum.151376.
［23］	Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phaseⅢ, randomised, controlled trial （PALACE 3）［J］. Ann Rheum Dis, 2016,75（6）:1065⁃1073. doi: 10.1136/annrheumdis⁃2015⁃207963.
［24］	Gladman DD, Kavanaugh A, Gómez⁃Reino JJ, et al. Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1⁃3 studies［J］. RMD Open, 2018,4（1）:e000669. doi: 10.1136/rmdopen⁃2018⁃000669.
［25］	Wells AF, Edwards CJ, Kivitz AJ, et al. Apremilast monotherapy in DMARD⁃naive psoriatic arthritis patients: results of the randomized, placebo⁃controlled PALACE 4 trial［J］. Rheumatology （Oxford）, 2018,57（7）:1253⁃1263. doi: 10.1093/rheumatology/key032.
［26］	Wells AF, Edwards CJ, Kivitz AJ, et al. Apremilast monotherapy for long⁃term treatment of active psoriatic arthritis in DMARD⁃naïve patients［J］. Rheumatology （Oxford）, 2022,61（3）:1035⁃1043. doi: 10.1093/rheumatology/keab449.
［27］	Mekhail C, Chouk M, Prati C, et al. Prognostic factors of good response to DMARDs in psoriatic arthritis: a narrative review［J］. Expert Rev Clin Pharmacol, 2020,13（5）:505⁃519. doi: 10. 1080/17512433.2020.1758556.
［28］	Torre Alonso JC, Almodóvar González R, Montilla Morales C, et al. Expert recommendations for the use of apremilast in psoriatic arthritis［J］. Reumatol Clin （Engl Ed）, 2023,19（1）:34⁃44. doi: 10.1016/j.reumae.2022.01.001.
［29］	Elyoussfi S, Thomas BJ, Ciurtin C. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies［J］. Rheumatol Int, 2016,36（5）:603⁃612. doi: 10.1007/s00296⁃016⁃3436⁃0.
［30］	Terui T, Okubo Y, Kobayashi S, et al. Efficacy and safety of apremilast for the treatment of Japanese patients with palmoplantar pustulosis: results from a phase 2, randomized, placebo⁃controlled study［J］. Am J Clin Dermatol, 2023,24（5）:837⁃847. doi: 10.1007/s40257⁃023⁃00788⁃2.
［31］	Kato N, Takama H, Ando Y, et al. Immediate response to apremilast in patients with palmoplantar pustulosis: a retrospective pilot study［J］. Int J Dermatol, 2021,60（5）:570⁃578. doi: 10.1111/ijd.15382.
［32］	Gioe OA, Savoie C, Grieshaber EB, et al. Treatment of erythrodermic psoriasis with apremilast［J］. JAAD Case Rep, 2021,11:36⁃37. doi: 10.1016/j.jdcr.2021.03.011.
［33］	Megna M, Ocampo⁃Garza SS, Fabbrocini G, et al. A case of erythrodermic psoriasis successfully treated with apremilast［J］. Dermatol Ther, 2022,35（1）:e15204. doi: 10.1111/dth.15204.
［34］	Krishnamoorthy G, Kotecha A, Pimentel J. Complete resolution of erythrodermic psoriasis with first⁃line apremilast monotherapy［J］. BMJ Case Rep, 2019,12（1）:e226959. doi: 10.1136/bcr⁃2018⁃226959.
［35］	Mugheddu C, Pizzatti L, Sanna S, et al. COVID⁃19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management［J］. J Eur Acad Dermatol Venereol, 2020,34（8）:e376⁃e378. doi: 10.1111/jdv.16625.
［36］	Papadavid E, Kokkalis G, Polyderas G, et al. Rapid clearance of erythrodermic psoriasis with apremilast［J］. J Dermatol Case Rep, 2017,11（2）:29⁃31. doi: 10.3315/jdcr.2017.1246.
［37］	Olisova OY, Svistunova DA, Anpilogova EM. Apremilast and NB⁃UVB combination therapy in moderate⁃to⁃severe plaque type psoriasis［J］. Int J Womens Dermatol, 2020,6（3）:225. doi: 10. 1016/j.ijwd.2020.03.012.
［38］	Fazeel ZA, Alhamyani SS, Jain S. Comparison of efficacy and safety of calcipotriol and apremilast combination against cacipotriol monotherapy in psoriasis［J］. Biomed Pharmacol J, 2021,14（4）: 2319⁃2326. doi:10.13005/bpj/2333.
［39］	Okubo Y, Takahashi H, Hino R, et al. Efficacy and safety of apremilast in the treatment of patients with mild⁃to⁃moderate psoriasis in Japan: results from PROMINENT, a phase 3b, open⁃label, single⁃arm study［J］. Dermatol Ther （Heidelb）, 2022,12（6）:1469⁃1480. doi: 10.1007/s13555⁃022⁃00747⁃5.
［40］	Hassanandani T, Panda M, Jena AK, et al. Methotrexate monotherapy versus methotrexate and apremilast combination therapy in the treatment of palmoplantar psoriasis: a prospective, randomised, assessor⁃blinded, comparative study［J］. Indian J Dermatol Venereol Leprol, 2023,89（2）:213⁃220. doi: 10.25259/IJDVL_843_2021.
［41］	Arias de la Rosa I, López⁃Montilla MD, Román⁃Rodríguez C, et al. The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast［J］. J Intern Med, 2022,291（5）:676⁃693. doi: 10.1111/joim.13447.
［42］	Menter A, Strober BE, Kaplan DH, et al. Joint AAD⁃NPF guidelines of care for the management and treatment of psoriasis with biologics［J］. J Am Acad Dermatol, 2019,80（4）:1029⁃1072. doi: 10.1016/j.jaad.2018.11.057.
［43］	AbuHilal M, Walsh S, Shear N. Use of apremilast in combination with other therapies for treatment of chronic plaque psoriasis: a retrospective study［J］. J Cutan Med Surg, 2016,20（4）:313⁃316. doi: 10.1177/1203475416631328.
［44］	Takamura S, Sugai S, Taguchi R, et al. Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue［J］. J Dermatol, 2020,47（3）:290⁃294. doi: 10. 1111/1346⁃8138.15193.
［45］	Reich K, Gooderham M, Green L, et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate⁃to⁃severe plaque psoriasis: 52⁃week results from a phaseⅢb, randomized, placebo⁃controlled trial （LIBERATE）［J］. J Eur Acad Dermatol Venereol, 2017,31（3）:507⁃517. doi: 10.1111/jdv.14015.
［46］	Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris ⁃ part 2: specific clinical and comorbid situations［J］. J Eur Acad Dermatol Venereol, 2021,35（2）:281⁃317. doi: 10.1111/jdv.16926.
［47］	Jiang Y, Chen Y, Yu Q, et al. Biologic and small⁃molecule therapies for moderate⁃to⁃severe psoriasis: focus on psoriasis comorbidities［J］. BioDrugs, 2023,37（1）:35⁃55. doi: 10.1007/s40259⁃022⁃00569⁃z.
［48］	Ferguson LD, Cathcart S, Rimmer D, et al. Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease⁃results of the Immune Metabolic Associations in Psoriatic Arthritis study［J］. Rheumatology （Oxford）, 2022,61（3）:1026⁃1034. doi: 10.1093/rheumatology/keab474.
［49］	Ikumi K, Torii K, Sagawa Y, et al. Phosphodiesterase 4 inhibitor apremilast improves insulin resistance in psoriasis patients［J］. J Dermatol, 2022,49（4）:e125⁃e126. doi: 10.1111/1346⁃8138. 16286.
［50］	Ikonomidis I, Pavlidis G, Kadoglou N, et al. Apremilast improves endothelial glycocalyx integrity, vascular and left ventricular myocardial function in psoriasis［J］. Pharmaceuticals （Basel）, 2022,15（2）:172. doi: 10.3390/ph15020172.
［51］	Gelfand JM, Shin DB, Armstrong AW, et al. Association of apremilast with vascular inflammation and cardiometabolic function in patients with psoriasis: the VIP⁃A phase 4, open⁃label, nonrandomized clinical trial［J］. JAMA Dermatol, 2022,158（12）:1394⁃1403. doi: 10.1001/jamadermatol.2022.3862.
［52］	Malara G, Politi C, Trifirò C, et al. Effectiveness of apremilast in real life in patients with psoriasis: a longitudinal study［J］. Acta Derm Venereol, 2021,101（9）:adv00545. doi: 10.2340/00015555⁃3846.
［53］	Danese S, Neurath MF, Kopoń A, et al. Effects of apremilast, an oral inhibitor of phosphodiesterase 4, in a randomized trial of patients with active ulcerative colitis［J］. Clin Gastroenterol Hepatol, 2020,18（11）:2526⁃2534.e9. doi: 10.1016/j.cgh.2019. 12.032.
［54］	Amgen Inc. Labels for NDA 205437. OTEZLA® （apremilast） tablets, for oral use［EB/OL］. （2024⁃04⁃25）［2024⁃12⁃23］. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/205 437Orig1s013correctedlbl.pdf.
［55］	Nast A, Spuls PI, van der Kraaij G, et al. European S3⁃Guideline on the systemic treatment of psoriasis vulgaris ⁃ update apremilast and secukinumab ⁃ EDF in cooperation with EADV and IPC［J］. J Eur Acad Dermatol Venereol, 2017,31（12）:1951⁃1963. doi: 10.1111/jdv.14454.
［56］	Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology⁃National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies［J］. J Am Acad Dermatol, 2020,82（6）:1445⁃1486. doi: 10.1016/j.jaad.2020.02.044.
［57］	National Institute for Health and Care Excellence. Apremilast for treating moderate to severe plaque psoriasis［EB/OL］. NICE, 2016（2016⁃11⁃23）［2024⁃05⁃15］. https://www.nice.org.uk/guidance/ta419.
［58］	Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate⁃to⁃severe plaque psoriasis［J］. J Eur Acad Dermatol Venereol, 2017,31（5）:774⁃790. doi: 10. 1111/jdv.14114.
［59］	Liu Y, Zhou S, Assaf M, et al. Impact of renal impairment on the pharmacokinetics of apremilast and metabolite M12［J］. Clin Pharmacol Drug Dev, 2016,5（6）:469⁃479. doi: 10.1002/cpdd. 256.
［60］	Assaf MS, Laille E, Liu L, et al. Pharmacokinetics and safety of apremilast （CC⁃10004） in subjects with hepatic impairment［J］. Int J Med Eng Inform, 2014,6（2）:100. doi: 10.1504/IJMEI.2014. 060246.
［61］	Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris ⁃ part 1: treatment and monitoring recommendations［J］. J Eur Acad Dermatol Venereol, 2020,34（11）:2461⁃2498. doi: 10.1111/jdv.16915.
［62］	Rademaker M, Agnew K, Andrews M, et al. Psoriasis in those planning a family, pregnant or breast⁃feeding. The Australasian Psoriasis Collaboration［J］. Australas J Dermatol, 2018,59（2）:86⁃100. doi: 10.1111/ajd.12641.
［63］	Belinchón I, Velasco M, Ara⁃Martín M, et al. Management of psoriasis during preconception, pregnancy, postpartum, and breastfeeding: a consensus statement［J］. Actas Dermosifiliogr （Engl Ed）, 2021,112（3）:225⁃241. doi: 10.1016/j.ad.2020.10. 002.
［64］	Paller AS, Hong Y, Becker EM, et al. Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: results from a phase 2 open⁃label study［J］. J Am Acad Dermatol, 2020,82（2）:389⁃397. doi: 10.1016/j.jaad. 2019.08.019.
［65］	Fiorillo L, Becker E, de Lucas R, et al. Efficacy and safety of apremilast in pediatric patients with moderate⁃to⁃severe plaque psoriasis: 16⁃week results from SPROUT, a randomized controlled trial［J］. J Am Acad Dermatol, 2024,90（6）:1232⁃1239. doi: 10.1016/j.jaad.2023.11.068.
［66］	Piaserico S, Messina F, Russo FP. Managing psoriasis in patients with HBV or HCV infection: practical considerations［J］. Am J Clin Dermatol, 2019,20（6）:829⁃845. doi: 10.1007/s40257⁃019⁃00457⁃3.
［67］	Reddy SP, Lee E, Wu JJ. Apremilast and phototherapy for treatment of psoriasis in a patient with human immunodeficiency virus［J］. Cutis, 2019,103（5）:E6⁃E7.
［68］	Sacchelli L, Patrizi A, Ferrara F, et al. Apremilast as therapeutic option in a HIV positive patient with severe psoriasis［J］. Dermatol Ther, 2018,31（6）:e12719. doi: 10.1111/dth.12719.
［69］	Shah BJ, Mistry D, Chaudhary N. Apremilast in people living with HIV with psoriasis vulgaris: a case report［J］. Indian J Dermatol, 2019,64（3）:242⁃244. doi: 10.4103/ijd.IJD_633_18.
［70］	Zarbafian M, Cote B, Richer V. Treatment of moderate to severe psoriasis with apremilast over 2 years in the context of long⁃term treated HIV infection: a case report［J］. SAGE Open Med Case Rep, 2019,7:2050313X19845193. doi: 10.1177/2050313X19845193.
［71］	Pullamsetti SS, Banat GA, Schmall A, et al. Phosphodiesterase⁃4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF［J］. Oncogene, 2013,32（9）:1121⁃1134. doi: 10.1038/onc.2012.136.
［72］	Bernardini N, Skroza N, Marchesiello A, et al. Psoriatic patients with a history of cancer: a real⁃life experience with apremilast treatment for 104 weeks［J］. Dermatol Ther, 2022,35（10）:e15306. doi: 10.1111/dth.15306.
［73］	Di Lernia V, Casanova DM, Ricci C. Apremilast in patients with history of malignancy: a real⁃life, single⁃center experience［J］. Int J Dermatol, 2021,60（1）:e22⁃e24. doi: 10.1111/ijd.15093.
［74］	Apalla Z, Psarakis E, Lallas A, et al. Psoriasis in patients with active lung cancer: is apremilast a safe option?［J］. Dermatol Pract Concept, 2019,9（4）:300⁃301. doi: 10.5826/dpc.0904a11.
［75］	Kurata M, Ohyama M. Long⁃term remission of severe nail psoriasis after discontinuation of apremilast in a colorectal cancer survivor［J］. J Dermatol, 2021,48（6）:e248⁃e249. doi: 10.1111/1346⁃8138.15831.
［76］	Foti C, Tucci M, Stingeni L, et al. Successful treatment with apremilast of severe psoriasis exacerbation during nivolumab therapy for metastatic melanoma［J］. Dermatol Ther, 2021,34（1）:e14653. doi: 10.1111/dth.14653.
［77］	Peitsch WK. Apremilast in a patient with psoriasis and mantle cell lymphoma under maintenance treatment with rituximab［J］. J Dtsch Dermatol Ges, 2019,17（3）:330⁃332. doi: 10.1111/ddg. 13771.
［78］	上海市医学会皮肤性病学分会, 上海市医学会肿瘤靶分子专科分会. 抗肿瘤药物相关皮肤不良反应管理专家共识［J］. 中华皮肤科杂志, 2023,56（10）:907⁃919. doi: 10.35541/cjd.2023 0084.
［79］	Apalla Z, Nikolaou V, Fattore D, et al. European recommendations for management of immune checkpoint inhibitors⁃derived dermatologic adverse events. The EADV task force 'Dermatology for cancer patients' position statement［J］. J Eur Acad Dermatol Venereol, 2022,36（3）:332⁃350. doi: 10. 1111/jdv.17855.
［80］	中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物制剂治疗指南（2021）［J］. 中华皮肤科杂志, 2021,54（12）:1033⁃1047. doi: 10.35541/cjd.20210643.
［81］	Goodman SM, Springer BD, Chen AF, et al. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty［J］. Arthritis Care Res （Hoboken）, 2022,74（9）:1399⁃1408. doi: 10.1002/acr.24893.
［82］	Albrecht K, Poddubnyy D, Leipe J, et al. Perioperative management of patients with inflammatory rheumatic diseases: updated recommendations of the German Society for Rheumatology［J］. Z Rheumatol, 2023,82（Suppl 1）:1⁃11. doi: 10.1007/s00393⁃021⁃01150⁃9.
［83］	Ghislain PD, Lambert J, Lam Hoai XL, et al. Real⁃life effectiveness of apremilast for the treatment of psoriasis in Belgium: results from the observational OTELO study［J］. Adv Ther, 2022,39（2）:1068⁃1080. doi: 10.1007/s12325⁃021⁃01981⁃7.
［84］	Koskivirta I, Ruotsalainen J, Kurki S, et al. Real⁃world registry⁃based study on apremilast use in psoriasis and psoriatic arthritis in Finland［J］. Scand J Rheumatol, 2023,52（5）:549⁃555. doi: 10.1080/03009742.2022.2151109.
［85］	Crowley J, Thaçi D, Joly P, et al. Long⁃term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials （ESTEEM 1 and 2）［J］. J Am Acad Dermatol, 2017,77（2）:310⁃317.e1. doi: 10.1016/j.jaad.2017.01.052.
［86］	Mease PJ, Hatemi G, Paris M, et al. Apremilast long⁃term safety up to 5 years from 15 pooled randomized, placebo⁃controlled studies of psoriasis, psoriatic arthritis, and Behçet's syndrome［J］. Am J Clin Dermatol, 2023,24（5）:809⁃820. doi: 10.1007/s40257⁃023⁃00783⁃7.
［87］	Langley A, Beecker J. Management of common side effects of apremilast［J］. J Cutan Med Surg, 2018,22（4）:415⁃421. doi: 10.1177/1203475417748886.
［88］	Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity［J］. Cell Signal, 2014,26（9）:2016⁃2029. doi: 10.1016/j.cellsig.2014. 05.014.
［89］	Torres T, Puig L. Apremilast: a novel oral treatment for psoriasis and psoriatic arthritis［J］. Am J Clin Dermatol, 2018,19（1）:23⁃32. doi: 10.1007/s40257⁃017⁃0302⁃0.
［90］	Speeckaert R, Lambert J, Puig L, et al. Vaccinations in patients receiving systemic drugs for skin disorders: what can we learn for SARS⁃Cov⁃2 vaccination strategies?［J］. Drugs R D, 2021,21（3）:341⁃350. doi: 10.1007/s40268⁃021⁃00349⁃0.

[1]	Bai Lu, Chu Yan, Liu Yuanyuan, Zhu Caiyong. Treatment of chronic hand eczema [J]. Chinese Journal of Dermatology, 2025, 58(5): 477-480.
[2]	Li Ziyu, Lu Yan. Paying attention to severe skin diseases after COVID-19 [J]. Chinese Journal of Dermatology, 2025, 58(4): 378-383.
[3]	Group on Pediatric Dermatology, China Dermatologist Association, Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on the diagnosis and treatment of pediatric pustular psoriasis in China （2025 version） [J]. Chinese Journal of Dermatology, 2025, 58(4): 297-306.
[4]	He Chunxia, Jin Hongzhong . Principles, current status, challenges and perspectives in the diagnosis and treatment of critical dermatological emergencies [J]. Chinese Journal of Dermatology, 2025, 58(4): 307-314.
[5]	Xu Zhuohong, Hu Yu, Gu Heng. Role of mesenchymal stem cell-derived exosomes in skin diseases [J]. Chinese Journal of Dermatology, 2025, 0(3): 20220881-e20220881.
[6]	Wang Wenqiu, Li Chengxin, Wang Rui. Biologics for the treatment of psoriasis relapse: current status [J]. Chinese Journal of Dermatology, 2025, 0(3): 20230301-e20230301.
[7]	Li Xiuzhen, Xu Xiulian. Effects of interleukin-23 inhibitors on psoriasis comorbidities [J]. Chinese Journal of Dermatology, 2025, 58(3): 268-272.
[8]	Lianghong Chen Yan SUN Jing-Yu WANG. Benvitimod for the treatment of dermatoses [J]. Chinese Journal of Dermatology, 2025, 58(3): 266-268.
[9]	Jin Lan, Qiu Yun, Wang Weijia, Kang Xiaojing, Ding Yuan. Clinical efficacy and safety of biological agents in the treatment of moderate-to-severe psoriasis in 124 elderly patients: a retrospective analysis [J]. Chinese Journal of Dermatology, 2025, 58(1): 47-52.
[10]	Wang Bo, Zheng Jie. Considerations in the treatment of elderly patients with psoriasis and atopic dermatitis using biologics and small-molecule drugs [J]. Chinese Journal of Dermatology, 2025, 58(1): 72-75.
[11]	Chen Jiaqi, Zhang Jin, Tang Jun. Relationships between coronavirus disease 2019 and psoriasis [J]. Chinese Journal of Dermatology, 2025, 58(1): 84-88.
[12]	Qiao Jiaxi, Xia Ping, Chen Liuqing. Analysis of dermoscopic and reflectance confocal microscopic features of psoriatic lesions before and after treatment with secukinumab [J]. Chinese Journal of Dermatology, 2024, 57(9): 825-829.
[13]	Dou Jinfa, Wang Jianbo, Zhang Shuai, Li Jianguo, Liu Hongwei, Zhang Shoumin. Analysis of changes in disease status and their influencing factors in patients with moderate to severe plaque psoriasis receiving biologic therapy during the coronavirus disease 2019 pandemic: a single-center cross-sectional study [J]. Chinese Journal of Dermatology, 2024, 57(8): 739-742.
[14]	Lin Ziyuan, Pang Tianyi, Wu Jingwen, Jin Hui, . Role of polycyclic aromatic hydrocarbons in the occurrence and development of inflammatory skin diseases [J]. Chinese Journal of Dermatology, 2024, 57(8): 765-769.
[15]	Sui Changlin, Chang Xiao, Zhao Qi, Zhu Wei. Psoriasis induced by anti-tumor targeted therapy and immunotherapy [J]. Chinese Journal of Dermatology, 2024, 57(6): 570-574.

Expert proposal on apremilast for the treatment of psoriasis （2025 edition）

PDF

Knowledge

Abstract

Cite this article

share this article

References ［90］

Related Articles 15

Metrics

Comments

Recommended 0